MXPA05005338A - Metodos para administrar dalbavancin para el tratamiento de infecciones bacterianas. - Google Patents

Metodos para administrar dalbavancin para el tratamiento de infecciones bacterianas.

Info

Publication number
MXPA05005338A
MXPA05005338A MXPA05005338A MXPA05005338A MXPA05005338A MX PA05005338 A MXPA05005338 A MX PA05005338A MX PA05005338 A MXPA05005338 A MX PA05005338A MX PA05005338 A MXPA05005338 A MX PA05005338A MX PA05005338 A MXPA05005338 A MX PA05005338A
Authority
MX
Mexico
Prior art keywords
dalbavancin
treatment
methods
bacterial infections
administering
Prior art date
Application number
MXPA05005338A
Other languages
English (en)
Spanish (es)
Inventor
Giorgio Mosconi
Original Assignee
Vicuron Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32330046&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA05005338(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vicuron Pharm Inc filed Critical Vicuron Pharm Inc
Publication of MXPA05005338A publication Critical patent/MXPA05005338A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
MXPA05005338A 2002-11-18 2003-11-14 Metodos para administrar dalbavancin para el tratamiento de infecciones bacterianas. MXPA05005338A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US42765402P 2002-11-18 2002-11-18
US48569403P 2003-07-08 2003-07-08
US49504803P 2003-08-13 2003-08-13
US49648303P 2003-08-19 2003-08-19
PCT/US2003/036127 WO2004045636A1 (en) 2002-11-18 2003-11-14 Methods of administering dalbavancin for treatment of bacterial infections

Publications (1)

Publication Number Publication Date
MXPA05005338A true MXPA05005338A (es) 2005-12-14

Family

ID=32330046

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05005338A MXPA05005338A (es) 2002-11-18 2003-11-14 Metodos para administrar dalbavancin para el tratamiento de infecciones bacterianas.

Country Status (14)

Country Link
US (12) US20050090433A1 (OSRAM)
EP (1) EP1565201B1 (OSRAM)
JP (3) JP5519090B2 (OSRAM)
KR (2) KR20120056310A (OSRAM)
AU (3) AU2003298662A1 (OSRAM)
CA (1) CA2506236C (OSRAM)
DK (1) DK1565201T3 (OSRAM)
ES (1) ES2712656T3 (OSRAM)
HU (1) HUE041133T2 (OSRAM)
IL (3) IL168327A (OSRAM)
MX (1) MXPA05005338A (OSRAM)
NO (1) NO20052362L (OSRAM)
PT (1) PT1565201T (OSRAM)
WO (3) WO2004045637A1 (OSRAM)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120056310A (ko) 2002-11-18 2012-06-01 비큐론 파마세티컬스 인코포레이티드 박테리아 감염 치료를 위한 달바반신 투여 방법
US20060074014A1 (en) * 2002-11-18 2006-04-06 Vicuron Pharmaceuticals Inc. Dalbavancin compositions for treatment of bacterial infections
US7119061B2 (en) * 2002-11-18 2006-10-10 Vicuron Pharmaceuticals, Inc. Dalbavancin compositions for treatment of bacterial infections
US20090062182A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched dalbavancin
US8389583B2 (en) * 2008-05-23 2013-03-05 Zurex Pharma, Inc. Antimicrobial compositions and methods of use
US20110132607A1 (en) * 2009-12-07 2011-06-09 Schlumberger Technology Corporation Apparatus and Technique to Communicate With a Tubing-Conveyed Perforating Gun
EP2969004A4 (en) 2013-03-15 2016-09-21 Melinta Therapeutics Inc METHOD FOR THE TREATMENT OF INFECTIONS IN OVERWEIGHT AND ADIPOSIVE PATIENTS USING ANTIBIOTICS
JP6540705B2 (ja) 2013-12-19 2019-07-10 ジーイー・ヘルスケア・バイオサイエンス・アクチボラグ 生物学的液体処理システムのための遠隔操作弁
HUE070928T2 (hu) 2014-07-17 2025-07-28 Melinta Therapeutics Llc Nagy tisztaságú oritavancin és eljárás annak elõállítására
JP6797795B2 (ja) 2014-11-06 2020-12-09 クセリア ファーマシューティカルズ エーピーエスＸｅｌｌｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ ＡｐＳ グリコペプチド組成物
KR102091852B1 (ko) * 2015-03-02 2020-03-23 코로나리콘셉츠 엘엘씨 Peg 대사산물 및 peg 분해 생성물 검정을 위한 화합물 및 방법
US10071141B2 (en) 2015-05-08 2018-09-11 Spectral Platforms, Inc. Albumin-based non-covalent complexes and methods of use thereof
US20200171124A1 (en) 2016-04-15 2020-06-04 Lupin Limited Topical compositions for ophthalmic and otic use
US11105747B2 (en) 2017-03-20 2021-08-31 Spectral Platforms, Inc. Spectroscopic methods to detect and characterize microorganisms
CA3069679A1 (en) * 2017-07-10 2019-01-17 Contrafect Corporation Blood component potentiation of lytic protein anti-bacterial activity and methods and uses thereof
CN110183519B (zh) * 2019-05-06 2023-04-11 大邦(湖南)生物制药有限公司 一种达巴万星关键中间体a40926的分离纯化方法
CN112480214B (zh) * 2020-12-14 2023-03-28 成都雅途生物技术有限公司 一种达巴万星关键中间体a40926的制备方法
EP4014965A1 (en) 2020-12-16 2022-06-22 EVER Valinject GmbH Aqueous solution
US20240083950A1 (en) 2021-01-11 2024-03-14 Xellia Pharmaceuticals Aps Synthesis process
CN115215926A (zh) * 2022-08-12 2022-10-21 丽珠集团福州福兴医药有限公司 达巴万星母核及其纯化方法、达巴万星及其合成方法
WO2024079224A1 (en) * 2022-10-12 2024-04-18 Xellia Pharmaceuticals Aps Liquid dalbavancin composition
AU2023359652A1 (en) * 2022-10-12 2025-05-29 Hikma Pharmaceuticals Usa Inc. Liquid dalbavancin composition
EP4431083A1 (en) 2023-03-16 2024-09-18 Adalvo Limited Formulation of dalbavancin
EP4431084A1 (en) 2023-03-16 2024-09-18 Adalvo Limited Formulation of dalbavancin
WO2025158262A1 (en) 2024-01-23 2025-07-31 Lupin Limited Stable pharmaceutical compositions of dalbavancin as ready-to-dilute formulation
GB202405996D0 (en) * 2024-04-29 2024-06-12 Arecor Ltd Novel compositions

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US541616A (en) * 1895-06-25 Elevator attachment
US573679A (en) * 1896-12-22 Apparatus for mowing hay
GB1496386A (en) * 1975-03-05 1977-12-30 Lepetit Spa Antibiotics
US4195079A (en) * 1979-01-31 1980-03-25 Pfizer Inc. New polycyclic ether antibiotic
CA1183789A (en) 1981-08-04 1985-03-12 Kiyoshi Isono Antibiotic 76-11, process for the production thereof, anticoccidiosis agent and domestic animals growth accelerator comprising the same as an effective ingredient
US4578271A (en) 1982-05-24 1986-03-25 Fujisawa Pharmaceutical Co., Ltd. Biologically active WS 6049 substances, a process for the production thereof and their pharmaceutical compositions
FI73697C (fi) * 1982-06-08 1987-11-09 Lepetit Spa Foerfarande foer framstaellning av individuella faktorer 1, 2, 3, 4 och 5 av teikomysin a2.
FR2548021B1 (fr) 1983-06-29 1986-02-28 Dick P R Compositions pharmaceutiques dermiques a action prolongee et continue a base d'acides gras essentiels
GB8415092D0 (en) * 1984-06-13 1984-07-18 Lepetit Spa Ester derivatives
GB8425685D0 (en) * 1984-10-11 1984-11-14 Lepetit Spa Antibiotic a 40926 complex
US4914187A (en) * 1984-11-13 1990-04-03 Gruppo Lepetit S.P.A Ester derivatives of antibiotic L 17046
GB8428619D0 (en) * 1984-11-13 1984-12-19 Lepetit Spa Derivatives of antibiotic l 17046
GB8512795D0 (en) 1985-05-21 1985-06-26 Lepetit Spa Increasing ratio of components of teicoplanin a2 complex
GB8531846D0 (en) 1985-12-30 1986-02-05 Lepetit Spa Antibiotic a 40926 mannosyl aglycon
GB8608809D0 (en) * 1986-04-11 1986-05-14 Lepetit Spa Antibiotic
GB8621911D0 (en) * 1986-09-11 1986-10-15 Lepetit Spa Increasing ratio of components of anti-biotic complex
GB8621912D0 (en) 1986-09-11 1986-10-15 Lepetit Spa Increasing ratio of components of anti-biotic complex
GR871488B (en) 1986-10-10 1987-11-12 Lepetit Spa New antibiotics
GB8715735D0 (en) * 1987-07-03 1987-08-12 Lepetit Spa De-mannosyl teicoplanin derivatives
US4882313A (en) * 1987-07-31 1989-11-21 Smithkline Beckman Corporation Carboxamide derivatives of glycopeptides
GB8726859D0 (en) 1987-11-17 1987-12-23 Lepetit Spa 22-dechlorotei-coplanins
US5004605A (en) * 1987-12-10 1991-04-02 Cetus Corporation Low pH pharmaceutical compositions of recombinant β-interferon
FR2628269B1 (fr) * 1988-03-04 1990-07-27 Sgs Thomson Microelectronics Dispositif de demarrage progressif d'une alimentation a decoupage
ES2083374T3 (es) 1988-12-27 1996-04-16 Lepetit Spa Derivados amidicos en posicion c63 de 34-des(acetilglucosaminil)-34-desoxi-teicoplaninas.
IE64155B1 (en) 1989-03-29 1995-07-12 Lepetit Spa New substituted alkylamide derivatives of teicoplanin
JPH03193735A (ja) 1989-12-22 1991-08-23 Shionogi & Co Ltd グリコペプチド系抗生物質の安定化組成物
US5030619A (en) * 1990-04-16 1991-07-09 Miles Inc. Synergistic fungicidal composition
US5606036A (en) * 1991-03-27 1997-02-25 Gruppo Lepetit Spa Antibiotic A 40926 ester derivatives
JP2783722B2 (ja) * 1991-07-12 1998-08-06 麒麟麦酒株式会社 スピカマイシン誘導体およびそれを含む抗腫瘍剤
US5750509A (en) * 1991-07-29 1998-05-12 Gruppo Lepetit S.P.A. Amide derivatives of antibiotic A 40926
HU223946B1 (hu) 1991-07-29 2005-03-29 Vicuron Pharmaceuticals Inc. Eljárás az A 40926 glikopeptid antibiotikum-származékai és az azokat hatóanyagként tartalmazó gyógyszerkészítmények előállítására
US6384013B1 (en) * 1992-03-19 2002-05-07 Eli Lilly And Company Cyclic peptide antifungal agents and process for preparation thereof
US5882900A (en) * 1992-09-10 1999-03-16 Gruppo Lepetit S.P.A. Process for the selective increase of production of antibiotic GE 2270 factor a by adding vitamin B12 to nutrient medium
CA2112776C (en) * 1993-01-21 2002-11-12 Masakazu Tsuchiya Process for inhibiting activity of endotoxin
WO1994025588A2 (en) * 1993-04-30 1994-11-10 Biognostik Gesellschaft für Biomolekulare Diagnostik mbH ANTISENSE-OLIGONUCLEOTIDES FOR THE TREATMENT OF IMMUNOSUPPRESSIVE EFFECTS OF TRANSFORMING GROWTH FACTOR-β (TGF-β)
ATE165101T1 (de) * 1995-02-07 1998-05-15 Biosearch Italia Spa Basische prolinamid derivate von ge2270 und ge2270-ahnlichten antibiotika
DE69615155T2 (de) * 1995-02-07 2002-01-17 Biosearch Italia S.P.A., Gerenzano Basische oxazolinamid-derivate von ge2270 und ge2270-änlichen antibiotika
SI9500039B (sl) * 1995-02-07 2002-02-28 Lek, Nov kombiniran postopek čiščenja Vankomicin hidroklorida
US5789308A (en) * 1995-06-06 1998-08-04 Advanced Micro Devices, Inc. Manufacturing method for wafer slice starting material to optimize extrinsic gettering during semiconductor fabrication
CA2180206A1 (en) * 1995-06-30 1996-12-31 Motoya Ohshika Freeze-dried preparation for pharmaceutical use
ATE274524T1 (de) * 1995-07-05 2004-09-15 Aventis Bulk S P A Reinigung von dalbeheptide-antibiotika mittels isoelektrofokussierung
DE19600590A1 (de) * 1996-01-10 1997-07-24 Tzn Forschung & Entwicklung Schutzvorrichtung für optische Systeme zur Vermeidung von Schäden bei Bestrahlung dieser Systeme mit Laserlicht
DK0880541T3 (da) * 1996-02-14 2003-05-05 Biosearch Italia Spa Derivater af antibiotikum GE2270-faktorer
AU2441697A (en) 1996-04-12 1997-11-07 Eli Lilly And Company Covalently-linked glycopeptide dimers
CA2250578C (en) * 1996-04-23 2003-06-24 Versicor Inc. Improved chemical process for preparing amide derivatives of antibiotic a 40926
US5935238A (en) * 1997-06-19 1999-08-10 Sun Microsystems, Inc. Selection from multiple fetch addresses generated concurrently including predicted and actual target by control-flow instructions in current and previous instruction bundles
JP4204655B2 (ja) * 1997-08-08 2009-01-07 株式会社ルネサステクノロジ パルス出力機能付マイクロコンピュータ
CA2255140A1 (en) 1997-12-23 1999-06-23 Eli Lilly And Company Echinocandin binding domain of 1,3-.beta.-glucan synthase
US6541616B1 (en) * 1998-10-01 2003-04-01 Antex Biologics Inc. Moraxella catarrhalis protein, gene sequence and uses thereof
US6417180B1 (en) 1998-10-07 2002-07-09 University Of Massachusetts Zinc finger-reactive antimicrobial compounds
JP4362017B2 (ja) * 1998-12-23 2009-11-11 セラヴァンス， インコーポレーテッド グリコペプチド誘導体およびそれを含有する薬学的組成物
TWI233805B (en) * 1999-07-01 2005-06-11 Fujisawa Pharmaceutical Co Stabilized pharmaceutical composition in lyophilized form as antifungal agent
WO2001083520A2 (en) 2000-05-02 2001-11-08 Theravance,Inc Polyacid glycopeptide derivatives
WO2003070756A2 (de) 2002-02-18 2003-08-28 Combinature Biopharm Ag Neue glycopeptid-antibiotika und verfahren zu deren synthetisierung
KR20120056310A (ko) 2002-11-18 2012-06-01 비큐론 파마세티컬스 인코포레이티드 박테리아 감염 치료를 위한 달바반신 투여 방법
US7119061B2 (en) * 2002-11-18 2006-10-10 Vicuron Pharmaceuticals, Inc. Dalbavancin compositions for treatment of bacterial infections

Also Published As

Publication number Publication date
NO20052362D0 (no) 2005-05-12
WO2004046196A3 (en) 2004-08-19
KR20050094396A (ko) 2005-09-27
US20050130914A1 (en) 2005-06-16
KR101173310B1 (ko) 2012-08-10
AU2003294262A1 (en) 2004-06-15
NO20052362L (no) 2005-08-17
US7115564B2 (en) 2006-10-03
AU2003294262B2 (en) 2007-08-23
IL230875A0 (en) 2014-03-31
JP5519090B2 (ja) 2014-06-11
US20040220122A1 (en) 2004-11-04
WO2004046196A2 (en) 2004-06-03
HK1083684A1 (en) 2006-07-07
US20090298748A1 (en) 2009-12-03
HUE041133T2 (hu) 2019-05-28
US20040224908A1 (en) 2004-11-11
WO2004045637A1 (en) 2004-06-03
CA2506236C (en) 2018-07-17
US6900175B2 (en) 2005-05-31
KR20120056310A (ko) 2012-06-01
HK1114014A1 (en) 2008-10-24
PT1565201T (pt) 2019-02-05
WO2004045636A1 (en) 2004-06-03
IL239913A0 (en) 2015-08-31
JP2006514092A (ja) 2006-04-27
US20040198715A1 (en) 2004-10-07
EP1565201B1 (en) 2018-10-31
CA2506236A1 (en) 2004-06-03
US20050004011A1 (en) 2005-01-06
AU2003299561A1 (en) 2004-06-15
DK1565201T3 (en) 2019-02-25
US20050130909A1 (en) 2005-06-16
ES2712656T3 (es) 2019-05-14
US20050032721A1 (en) 2005-02-10
IL168327A (en) 2014-02-27
JP2013155188A (ja) 2013-08-15
AU2003298662A1 (en) 2004-06-15
US20050090433A1 (en) 2005-04-28
EP1565201A1 (en) 2005-08-24
US20040142883A1 (en) 2004-07-22
US20090305953A1 (en) 2009-12-10
US20040197415A1 (en) 2004-10-07
IL239913B (en) 2019-01-31
JP2011157381A (ja) 2011-08-18

Similar Documents

Publication Publication Date Title
MXPA05005338A (es) Metodos para administrar dalbavancin para el tratamiento de infecciones bacterianas.
WO2006078277A3 (en) Dalbavancin compositions for treatment of bacterial infections
WO2003096990A3 (en) Protein cages for the delivery of medical imaging and therapy
DE60239707D1 (de) Antimikrobielle kationische peptide und diese enthaltende formulierungen
WO2004093831A3 (en) Cytokine-expressing cellular vaccine combinations
WO2003099110A3 (en) Herbs and herbal combinations useful for the treatment of microbial infections
EP1503788A4 (en) TREATMENT OF ALPHA GALACTOSIDASE A LACK
WO2005096990A3 (en) Novel modification of medical prostheses
MXPA03010085A (es) Composiciones y su uso en la hiperplasia.
WO2005027842A8 (en) Combinations of drugs for the treatment of neoplasms
WO2004006858A3 (en) Compounds, compositions, and methods employing same
GB0217294D0 (en) Medicaments
EP4588513A3 (en) Methods of treating gout
MXPA05013974A (es) Formulaciones farmaceuticas de compuestos de inhibicion amiloidea.
SG162614A1 (en) Bicyclic 6-alkylidene-penems as beta-lactamases inhibitors
TW200511999A (en) Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and parathyroid hormone
IL173878A0 (en) Use of tigecycline, alone, or in combination with rifampin to treat osteomyelitis and/or septic arthritis
WO2005042699A3 (en) Modified polypeptides with therapeutic activity and methods of use
WO2004010934A3 (en) Methods for the use of neurotoxin in the treatment of urologic disorders
WO2003007876A3 (en) N-fatty acid-amino acid conjugates and therapeutic uses
CY1107038T1 (el) Μεθοδος θεραπειας βακτηριακων λοιμωξεων με χρηση της γεμιφλοξασινης ή ενος αλατος αυτης και ενος αντιβιοτικου β-λακταμης
WO2005000239A3 (en) Lyase treatment for p. carinii
IL174134A0 (en) Use of a protein in the preparation of a medicament for treatment of fibrotic diseases
WO2005004880A8 (en) Vaginal compositions for treating pelvic tissue infections and traumas
CY1108472T1 (el) Μεθοδος για θεραπεια βακτηριακων μολυνσεων με χρηση γεμιφλοξακινης ή ενος αλατος αυτης και ενα αντιβακτηριακο παραγοντα καρβαπενεμης

Legal Events

Date Code Title Description
FG Grant or registration